La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Exscientia Gestione

Gestione criteri di controllo 1/4

Exscientia's Il CEO è Dave Hallett, nominato in Feb2023, ha un mandato di 1.5 anni. possiede direttamente 0.001% delle azioni della società, per un valore di € 7.43K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 3.6 anni.

Informazioni chiave

Dave Hallett

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.6yrs
Proprietà del CEO	0.001%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Dave Hallett (55 yo)

1.6yrs

Mandato

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallett	Chief Scientific Officer	1.6yrs	Nessun dato	0.0012% £ 7.1k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 232.6k
John Overington	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Sara Sherman	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Dan Ireland	Executive VP of Legal & Company Secretary	1.7yrs	Nessun dato	Nessun dato
Parker Moss	Executive Vice President of Corporate Development	less than a year	Nessun dato	Nessun dato
Caroline Rowland	Chief People Officer	2yrs	Nessun dato	Nessun dato
Richard Law	Chief Business Officer	no data	Nessun dato	Nessun dato
Nikolaus Krall	Executive Vice President of Precision Medicine	1.7yrs	Nessun dato	Nessun dato
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	Nessun dato	Nessun dato

1.6yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 0RK non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallett	Chief Scientific Officer	less than a year	Nessun dato	0.0012% £ 7.1k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 232.6k
Elizabeth Crain	Independent Non-Executive Chairman	3.6yrs	UK£282.03k	0.055% £ 334.7k
Mario Polywka	Independent Non-Executive Director	7yrs	UK£201.69k	0.045% £ 274.2k
Robert Ghenchev	Independent Non-Executive Director	4.3yrs	Nessun dato	Nessun dato
Franziska Michor	Independent Director	1.3yrs	UK£178.86k	0.0051% £ 31.4k

3.7yrs

Durata media

51yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0RK sono considerati esperti (durata media dell'incarico 3.6 anni).

Exscientia Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Third quarter 2022 earnings released: UK£0.29 loss per share (vs UK£59.17 loss in 3Q 2021)

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Less than half of directors are independent

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

High number of new directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media